Newsylist real-time news trend intelligence
▲ Peaking Health

Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients

A first-in-human clinical trial for a mutant KRAS vaccine shows promise in preventing pancreatic cancer among high-risk patients.

4sources
4articles
10velocity
+0%since first seen
46m agofirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

10730Jul 22 17:29Jul 22 19:29 UTC

The brief

Early data from a Phase 1 clinical trial indicates that an mKRAS vaccine is capable of preventing pancreatic cancer in high-risk individuals. The treatment has been shown to elicit durable T-cell responses in patients with pancreatic ductal adenocarcinoma (PDAC).

Coverage from Fox News, The Scientist, Oncodaily, and CancerNetwork emphasizes that these first-in-human results are encouraging. Anna Berkenblit is cited in reports regarding the early data of the mutant KRAS vaccine.

Future focus remains on the progression of the vaccine's efficacy following these initial Phase 1 trial results.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 40m ago.

Quick answers

What is the name of the vaccine being tested?

The vaccine is referred to as the mKRAS vaccine.

What stage of testing is the vaccine currently in?

The vaccine has shown promise in a Phase 1 clinical trial.

Who is the target group for this vaccine?

The vaccine is designed for high-risk patients to prevent the onset of pancreatic cancer.

Coverage (4)

People, places & organizations

Topics

Related trends